ClinicalTrials.gg
CompletedNCT03433534NIVEALUpdated Nov 12, 2019

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer

An observational study in Kidney Cancer and Lung Cancer, sponsored by University Hospital, Tours. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by University Hospital, Tours · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
64
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Kidney Neoplasms with a site in France — 31 open to participants now, 36 under way, 4 of them phase 3. Kidney Neoplasms · France.

Enrollment
23rd of 30
64 · median 163
Started
2018
with 8 others
Observational
30 of 108
7 open now
Registered
55th of 108
by date

Among the 108 studies in Kidney Neoplasms with a site in France, this one is the 23rd largest by enrollment of the 30 observational ones that give a count, is one of 9 that started in 2018, is one of 30 observational ones, and was the 55th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 209 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

31 of the 108 studies in Kidney Neoplasms with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 172 Kidney Neoplasms studies recruiting now, 132 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Kidney Neoplasms with a site in France, or all of them as a file.
02

Study summary

To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood concentration.

Collection of standard data prospectively.

Read the detailed description

Nivolumab is a monoclonal antibody used for the treatment of non small cell lung carcinoma and renal cell carcinoma. Huge variability exists between patients treated by nivolumab in terms of efficacy and side effects. Like others monoclonal antibodies, a relation between concentration and effects of nivolumab may exist.

The aim of this study is to assess the relationship between blood concentration of nivolumab and progression free survival, overall survival and side effects on the one hand, and on the other to describe pharmacokinetic of nivolumab

03

Conditions studied

  • Kidney Cancer
  • Lung Cancer

Keywords

  • nivolumab
  • monoclonal antibody
  • Opdivo
  • antineoplastic agent
  • ELISA
  • pharmacokinetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated with nivolumab at CHRU of Tours for squamous or non squamous non small cell lung cancer stage IV or renal cell carcinoma stage IV

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with squamous or non squamous non small cell lung cancer stage IV or patient with renal cell carcinoma stage IV
  • Patient receiving nivolumab or who will receive nivolumab
  • Age ⩾ 18 years old
  • OMS stage ≤ 2
  • Evaluable disease

Exclusion criteria

Exclusion Criteria:

  • Active not treated before by surgery or radiotherapy
  • disease
  • Patient having objected to the processing of his data
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
64 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Pharmacokinetic of Nivolumab

    Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.

    Other: Pharmacokinetic of Nivolumab

Interventions

  • OtherPharmacokinetic of Nivolumab

    Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.

    Also known as: Opdivo

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Association between nivolumab concentration and progression free survival : time from start of nivolumab treatment to progression

    Time frame: Up to one year

Secondary outcomes

  1. Overall survival

    Association between nivolumab concentration and overall survival : time from start of nivolumab treatment to death

    Time frame: Up to one year

  2. Target concentration

    Determination of nivolumab concentration associated with clinical benefit (complete response + partial response + stable disease)

    Time frame: 14 days

  3. Side effects

    Association between nivolumab residual concentration and side effects

    Time frame: 14 days

  4. Nivolumab PK parameters : distribution volume

    Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).

    Time frame: Baseline up to one year

  5. Nivolumab PK parameters : clearance

    Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).

    Time frame: Baseline up to one year

07

Study locations

2 sites
  • Medical oncology department, University Hospital, Tours
    Tours, 37044, France
  • Pneumology department, University Hospital, Tours
    Tours, 37044, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2018, 10 months.

Of 89 non-industry observational studies under Kidney Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34. This study's 10 months is below that.

Counting every sponsor, half of 107 studies reached it within 74 months; a quarter within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Feb 14, 2018
StartActual
Jan 29, 2018
Primary completionActual
Dec 21, 2018
CompletionActual
Dec 21, 2018
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03433534
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Jan 29, 2018
Primary completion
Dec 21, 2018
Completion
Dec 21, 2018
Last update
Nov 12, 2019

Study contacts

Claude Linassier
study director · University Hospital, Tours

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion